Cita APA

Ascierto, P. A., Dreno, B., Larkin, J., Ribas, A., Cruz Merino, L. d. l., & McArthur, G. A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study.

Citación estilo Chicago

Ascierto, Paolo Antonio, Brigitte Dreno, James Larkin, Antoni Ribas, Luis de la Cruz Merino, y Grant A. McArthur. 5-year Outcomes With Cobimetinib Plus Vemurafenib in BRAFV600 Mutation⇓positive Advanced Melanoma: Extended Follow-up of the CoBRIM Study. 2021.

Cita MLA

Ascierto, Paolo Antonio, et al. 5-year Outcomes With Cobimetinib Plus Vemurafenib in BRAFV600 Mutation⇓positive Advanced Melanoma: Extended Follow-up of the CoBRIM Study. 2021.